Statins and antiplatelet agents are associated with changes in the circulatory markers of endothelial dysfunction in chronic kidney disease.
El uso de estatinas y antiagregantes se asocia con cambios en los marcadores de disfunción endotelial en la enfermedad renal crónica.
Adult
Advanced Oxidation Protein Products
/ blood
Aged
Biomarkers
/ blood
Cell-Derived Microparticles
/ drug effects
Cross-Sectional Studies
Endothelium, Vascular
/ physiopathology
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Male
Middle Aged
Platelet Aggregation Inhibitors
/ adverse effects
Renal Insufficiency, Chronic
/ blood
Vascular Endothelial Growth Factor A
/ blood
Antiagregantes plaquetarios
Antiplatelet agents
Chronic kidney disease
Disfunción endotelial
Endothelial dysfunction
Endothelial microvesicles
Estatinas
Insuficiencia renal crónica
Microvesículas endoteliales
Statins
Journal
Nefrologia
ISSN: 2013-2514
Titre abrégé: Nefrologia (Engl Ed)
Pays: Spain
ID NLM: 101778581
Informations de publication
Date de publication:
Historique:
received:
01
02
2018
revised:
21
07
2018
accepted:
09
11
2018
pubmed:
9
2
2019
medline:
8
5
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Patients with chronic kidney disease (CKD) have higher risk of developing cardiovascular disease. In CKD patients the mechanisms involved in, endothelial damage and the role of different drugs used on these patients are not completely understood. The aim of this work is to analyze the effect of statins and platelet antiaggregant (PA) on endothelial microvesicles (EMVs) and other markers of endothelial dysfunction. Cross-sectional study of 41 patients with CKD 3b-4 and 8 healthy volunteers. Circulating levels of EMVs, vascular endothelial growth factor (VEGF), and advance oxidized protein products (AOPPS) were quantified and the correlation with different comorbidity variables and therapeutic strategies were evaluated. EMVs are increased in CKD patients as compared with controls (171.1 vs. 68.3/μl, P<.001). It was observed a negative correlation between age and EMVs. Statins and PA were associated with a reduction in EMVs and VEGF levels, independently of the serum total cholesterol levels (TC). The levels of AOPPS and VEGF were not different in CKD vs. controls. CKD is associated with a change in EMVs, VEGF and AOPP levels. The treatment with statins and PA normalizes these values to almost the observed in controls and this effect is independently of the prevailing TC level. These findings explain the existence of the pleiotropic effects of statins and PA which deserve further studies.
Sections du résumé
BACKGROUNDS AND PURPOSES
Patients with chronic kidney disease (CKD) have higher risk of developing cardiovascular disease. In CKD patients the mechanisms involved in, endothelial damage and the role of different drugs used on these patients are not completely understood. The aim of this work is to analyze the effect of statins and platelet antiaggregant (PA) on endothelial microvesicles (EMVs) and other markers of endothelial dysfunction.
EXPERIMENTAL APPROACH
Cross-sectional study of 41 patients with CKD 3b-4 and 8 healthy volunteers. Circulating levels of EMVs, vascular endothelial growth factor (VEGF), and advance oxidized protein products (AOPPS) were quantified and the correlation with different comorbidity variables and therapeutic strategies were evaluated.
RESULTS
EMVs are increased in CKD patients as compared with controls (171.1 vs. 68.3/μl, P<.001). It was observed a negative correlation between age and EMVs. Statins and PA were associated with a reduction in EMVs and VEGF levels, independently of the serum total cholesterol levels (TC). The levels of AOPPS and VEGF were not different in CKD vs. controls.
CONCLUSION
CKD is associated with a change in EMVs, VEGF and AOPP levels. The treatment with statins and PA normalizes these values to almost the observed in controls and this effect is independently of the prevailing TC level. These findings explain the existence of the pleiotropic effects of statins and PA which deserve further studies.
Identifiants
pubmed: 30732927
pii: S0211-6995(18)30219-4
doi: 10.1016/j.nefro.2018.11.001
pii:
doi:
Substances chimiques
Advanced Oxidation Protein Products
0
Biomarkers
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Platelet Aggregation Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
287-293Informations de copyright
Copyright © 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.